It is important to note that there are methodological limitations to our study. First, to maximize the quality of our data, we limited the sample to Knight ADRC participants with biomarker‐confirmed AD dementia and available longitudinal clinical data within 5 years. This restricted both our sample size and our sample demographics, potentially limiting the generalizability of the results from the highly engaged longitudinal research cohort with biomarker‐confirmed AD to a general population. Of note, we did not exclude participants with clinically significant magnetic resonance imaging (MRI) lesions suggestive of vascular or other non‐AD causes of dementia. This is similar to the donanemab trial 32 but differs from the lecanemab trial. 33 Second, we assumed that CDR‐SB progression is linear and that treatment effects occur uniformly during the observed study period, and that they extend at the same linear rate beyond the length of the study. Based on other studies, 34 cognition declines in a “waterfall” shape, suggesting that early reduction of decline may have even greater benefits at later time points. Third, we did not directly investigate the loss of
